An Observational Drug Utilization Study of SYCREST (Asenapine) in the United Kingdom

Trial Profile

An Observational Drug Utilization Study of SYCREST (Asenapine) in the United Kingdom

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Asenapine (Primary) ; Amisulpride; Aripiprazole; Clozapine; Iloperidone; Lurasidone; Olanzapine; Paliperidone; Quetiapine; Risperidone; Sertindole; Ziprasidone; Zotepine
  • Indications Bipolar disorders
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 09 Nov 2017 Planned End Date changed from 31 Oct 2017 to 18 Dec 2017.
    • 09 Nov 2017 Planned primary completion date changed from 31 Oct 2017 to 18 Dec 2017.
    • 06 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top